News

PharmaTher Secures FDA Approval for KETARx™ Ketamine Therapy

PharmaTher Secures FDA Approval for KETARx™ Ketamine Therapy

PharmaTher Achieves FDA Approval for KETARx™

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is thrilled to announce the approval of KETARx™, its innovative ketamine-based product, by the U.S. Food and Drug Administration (FDA). This landmark achievement is a game-changer in surgical pain management and establishes PharmaTher’s standing as a key player in the burgeoning psychedelic pharmaceutical market.

CEO's Vision for the Future

Fabio Chianelli, the driving force behind PharmaTher and its CEO, expressed his enthusiasm regarding this monumental achievement. He stated, "Today marks a new chapter for PharmaTher. Having secured FDA approval for KETARx™, we are poised to become a global leader in the ketamine pharmaceutical sector." His comments underscore the Company’s dedication to leveraging ketamine's potential across various therapeutic areas, particularly in addressing mental health, neurological issues, and pain management.

The Expanding Ketamine Market

Ketamine is unique in the world of psychedelics. It holds a distinguished place on the World Health Organization's Model List of Essential Medicines, which recognizes its importance. The global market for ketamine is currently valued at around $750 million and is projected to soar to $3.42 billion by 2034, representing an impressive compound annual growth rate of 16.4%. With the success of related products, such as SPRAVATO® (esketamine), which is expected to generate significant revenue, the landscape for ketamine-based therapies is filled with potential.

Strategic Development Areas

Part of PharmaTher’s strategy includes developing KETARx™ to target a broad spectrum of therapeutic avenues. These include tackling mental health conditions such as depression and neurodegenerative disorders like Parkinson's disease and Amyotrophic Lateral Sclerosis (ALS). Additionally, KETARx™ is positioned to address chronic and rare pain management issues, including Complex Regional Pain Syndrome (CRPS).

The Urgent Need for Reliable Ketamine Supply

Since February 2018, ketamine has consistently appeared on the FDA’s drug shortage list. This situation has led to a pressing need for a reliable supply of high-quality ketamine products. The FDA issued a risk alert highlighting concerns around compounded ketamine products and their use in psychiatric treatment, emphasizing the importance of approved therapies like KETARx™.

Supporting Mental Health Initiatives for Veterans

The focus on mental health support extends to veterans, who often face significant challenges related to PTSD, chronic pain, and depression. The Veterans Health Administration has endorsed and funds ketamine infusions, recognizing their effectiveness for military personnel. This initiative aligns with the larger mission of expanding legal access to psychedelic therapies to provide comprehensive relief for those in need.

Looking Ahead with Confidence

The FDA’s approval of KETARx™ reinforces PharmaTher’s commitment to innovation in the pharmaceutical sector. Recent initiatives by FDA Commissioner Marty Makary to expedite access to effective treatments imply that KETARx™ may enjoy further regulatory support, enhancing its availability for patients.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. is dedicated to unlocking the pharmaceutical benefits of ketamine for mental health, neurological, and pain disorders. As they move forward with KETARx™, the Company remains committed to improving patient outcomes and advancing therapeutic options.

For any inquiries concerning PharmaTher Holdings Ltd., please reach out to:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

Frequently Asked Questions

What is KETARx™?

KETARx™ is PharmaTher's ketamine-based product intended for managing surgical pain and potentially addressing various mental health disorders.

How does FDA approval impact PharmaTher?

FDA approval is a significant milestone that validates PharmaTher's efforts and opens doors for expanded clinical development and market opportunities.

What are the benefits of ketamine in mental health?

Ketamine has shown promise in treating mental health conditions like depression and PTSD by providing rapid relief for some patients.

Is there a shortage of ketamine products?

Yes, ketamine has frequently appeared on the FDA's drug shortage list, highlighting the need for reliable sources of this medication.

What is the future outlook for ketamine therapies?

The global ketamine market is projected to grow significantly, fueled by increasing acceptance of its use in mental health treatment and pain management.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SiBionics and PharmaSens Unveil Diabetes Tech at EASD

Updated Category News Views 2

Shaking Up Diabetes Care: New Tech Unveiled Imagine a world where managing diabetes isn't a juggling act with multiple devices. That's precisely the future SiBionics and PharmaSens are pitching at the European Association for the Study of Diabetes (EASD) 2026 in Milan. Now, let me tell you, these guys aren't just playing around with ideas; they're aiming to radically...

Continue Reading
ARTBOX Brings Korean Lifestyle Magic to LA Pop-Up

Updated Category News Views 3

ARTBOX: From Seoul to La-La Land Here's what caught my eye. It's 2026, and Korean lifestyle retailer ARTBOX is making a splash in the U.S.—kicking things off with a pop-up in LA. Now, usually, I'd be skeptical about pop-ups, but you've got to admire the audacity and timing here. They've picked Melrose Avenue, a hotspot for all things trendy, to introduce their mix of...

Continue Reading
Lawsuit Highlights Inaction in School Bus Tragedy

Updated Category News Views 3

Seeking Justice Amid Heartbreak Tragedy rarely arrives whispered on the wind—more often, it's the train wreck some saw coming long before it hits. The tragic death of Jenna Menias, a 6-year-old from Frankfort, Illinois, falls squarely in this camp. The family's legal lions, Corboy & Demetrio, have slapped two school districts—District 210 and 157-C—with a wrongful...

Continue Reading
Monster Energy Dominates Skateboard Podium at SLS Paris

Updated Category News Views 3

Monster Energy's Skateboard Triumph Hold the front page, because Monster Energy just pulled off a clean sweep in Paris. The company's team riders dominated the Men's Skateboard Street competition at the SLS Paris 2026, with the iconic Nyjah Huston snagging the top spot. It's a story filled with triumph, grit, and a dash of raw talent in a vibrant field of international...

Continue Reading
Class Action Alerts: M&A Under Scrutiny

Updated Category News Views 3

Unpacking Monteverde's M&A Investigations Hold your horses, folks! The M&A Class Action Firm is stirring the pot with its latest inquiries into some high-profile mergers. We're looking at Lisata Therapeutics, Flag Ship Acquisition Corporation, Baldwin Insurance Group, and ACV Auctions. So what's got Juan Monteverde's legal eagles swooping in on these deals? Well, are we...

Continue Reading
Power Knot MEA Wins THE BIZZ 2026 for Excellence

Updated Category News Views 3

Setting the Pace in Waste Management If there's one thing that sticks in my craw, it's how businesses handle food waste. Power Knot Middle East (PKME) seems to have cracked the code by not just leading the charge in organic waste management but also bagging THE BIZZ 2026 award. They’re not just playing industry games; PKME's pulling the strings with real leadership and...

Continue Reading
Monteverde's Equity Alert: Scrutinizing Recent M&A Deals

Updated Category News Views 3

Diving Into M&A Deals Under Monteverde's Lens Wall Street’s not just about suits and skyscrapers; it’s about the nitty-gritty of deals and whether those numbers add up in the investor's favor. So, when Monteverde & Associates PC throws its weight into scrutinizing mergers and acquisitions, you better believe it's worth a second look. See, they’re digging into four...

Continue Reading
Monteverde Probes Four Key M&A Deals for Fairness

Updated Category News Views 4

Examining the Intricacies of Pending M&A The merger and acquisition landscape can be vicious, especially when the sharks—those pesky class action lawyers—start circling. And let me tell you, Monteverde & Associates PC is diving headfirst into the fray, launching inquiries into a handful of these deals. This isn't your first stroll down Wall Street if you’ve seen one...

Continue Reading
Blokees Unveils 90+ New Wonders at Shanghai Fest

Updated Category News Views 3

A Grand Stage for New Arrivals Picture this: In the bustling and glittering chaos that was the Wonder Festival Shanghai 2026, held from October 3 to 4, Blokees laid down a major marker. More than 500 products, an artillery of imagination and craftsmanship, were on deck across their key lines—Blokees Model Kits and BLOKEES WHEELS. With 90 brand-new creations making their...

Continue Reading
Black Culture Icon: Plastic-Covered Couch Takes Stage

Updated Category News Views 3

A Plastic-Laden Piece of History Makes Art Who'd have thought a plastic-covered couch would turn into a cultural artifact? This iconic staple in Black households has done just that, debuting at Brooklyn's CultureCon in a fresh guise. It's more than just an upcycled furniture piece; it's a living archive that encapsulates Black culture, joy, and resilience. The Heart...

Continue Reading

Top 5 Most Recently Viewed Articles

TAT Technologies Expands Offering with Additional Share Purchase

Updated Category News Views 255

TAT Technologies Completes Full Exercise of Underwriters' Option TAT Technologies Ltd. (Nasdaq: TATT), a prominent provider of diverse products and services within the aerospace and defense sectors, recently finalized the full exercise of its underwriters' option to purchase additional ordinary shares. This closing marks a significant advancement in TAT's ongoing public...

Continue Reading
Navigating Young Americans' Debt: A Digital Approach to Relief

Updated Category News Views 209

Exploring the Rising Unsecured Debt Among Young Americans Recent findings indicate a dramatic rise in unsecured debt among young Americans, specifically Generation Z and young millennials. Financial wellness nonprofit Money Management International (MMI) has highlighted that young individuals seeking financial counseling have seen their debt levels more than double since...

Continue Reading
Investigation Into MediaAlpha, Inc. By Leading Law Firm

Updated Category News Views 173

Investigation Launched into MediaAlpha, Inc. Glancy Prongay & Murray LLP, known as a leading national shareholder rights law firm, has begun an investigation into MediaAlpha, Inc. This inquiry is being conducted on behalf of investors who may have been affected by possible violations of federal securities laws by the company. The Allegations Against MediaAlpha, Inc....

Continue Reading
UVA Cancer Center Joins Caris Precision Oncology Alliance

Updated Category News Views 56

UVA Cancer Center Joins the Caris Precision Oncology Alliance UVA Cancer Center has officially joined the Caris Precision Oncology Alliance (Caris POA), a significant network dedicated to advancing precision medicine and cancer treatment. Caris Life Sciences is thrilled to welcome this esteemed institution, recognized for its commitment to enhancing patient outcomes...

Continue Reading
Revolutionizing Trading: TruTrade's Approach to Capital Access

Updated Category News Views 118

Transforming Access to Capital in Trading In the competitive landscape of trading, both professional and independent traders are realizing that success is no longer just about having the best strategies. Instead, the focus is shifting towards scalable capital infrastructure, a crucial element that can enhance one’s trading performance. Introducing QuickFund AI—a...

Continue Reading